TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential
Here's Why Arcutis Biotherapeutics (NASDAQ:ARQT) Can Manage Its Debt Despite Losing Money
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
Arcutis Biotherapeutics Promotes Vairavan to CFO as Topper Plans Retirement
Arcutis Biotherapeutics: Topper Will Continue to Serve as CFO Until 1Q 10-Q Filing, Provide Transition Support >ARQT
Express News | Arcutis Biotherapeutics Inc - Latha Vairavan to Assume Role of CFO at Arcutis
Express News | Arcutis Announces Chief Financial Officer Transition
Press Release: Arcutis Announces Chief Financial Officer Transition
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BIZCLIK MEDIA PUBLISHES APRIL EDITION OF HEALTHCARE DIGITAL
Arcutis Biotherapeutics CFO Makes Significant Stock Sale!
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $21
Express News | Guggenheim Reiterates Buy on Arcutis Biotherapeuticsto Buy
Express News | Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $20 Price Target
Strategic Advantage and Market Confidence: Arcutis Biotherapeutics' Extended Exclusivity and Buy Rating Amidst Competitive Risks